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 The antitumor 3'-ethynyl nucleosides, 1-(3-C-ethynyl-β-D-ribopentofuranosyl)cytosine 
(ECyd) and 1-(3-C-ethynyl-β-D-ribopentofuranosyl)uracil (EUrd), are potent inhibitors of RNA 
polymerases and show excellent antitumor activity against various human solid tumors in 
xenograft models. ECyd is being investigated in phase I clinical trials as a novel anticancer drug 
possessing a unique antitumor action. ECyd and EUrd require the activity of uridine/cytidine 
kinase (UCK) to produce the corresponding active metabolite (ECTP and EUTP). The UCK 
family consists of two members, UCK1 and UCK2, and both UCKs are expressed in many 
tumor cells. It was unclear, however, whether UCK1 or UCK2 is responsible for the 
phosphorylation of the 3'-ethynyl nucleosides. We therefore established cell lines that are highly 
resistant to the 3'-ethynyl nucleosides from human fibrosarcoma HT-1080 and gastric carcinoma 
NUGC-3. All the resistant cell lines showed a high cross-resistance to ECyd and EUrd. As a 
result of cDNA sequence analysis, we found that UCK2 mRNA expressed in EUrd-resistant 
HT-1080 cells has a 98-base pair deletion of exon 5, whereas EUrd-resistant NUGC-3 cells were 
harboring the point mutation at nucleotide position 484 (C to T) within exon 4 of UCK2 mRNA. 
This mutation was confirmed by genome sequence analysis of the UCK2 gene. In 
ECyd-resistant NUGC-3 cells, the substitution of G to A at 391 nt of cording region of UCK2 
cDNA (Val to Met at codon 131) was found. Moreover, the expression of UCK2 protein and the 
enzymatic activity were decreased in these resistant cells. In contrast, no mutation in the mRNA 
or differences in protein expression levels of UCK1 were shown in all the resistant cells. These 
results suggest that UCK2 is responsible for the phosphorylation and activation of the antitumor 
3'-ethynyl nucleosides. Although UCK2 is expressed in many types of tissues and tumor cells, 
the expression level of UCK2 appears to be very diverse in cells. UCK2 may be a useful marker 
to predict chemosensitivity to antitumor uridine and cytidine analogs including EUrd and ECyd. 
In addition, UCK2 may be a novel molecular target for biochemical modulation to potentiate 
antitumor effects of such nucleoside analogs. 
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